Myelofibrosis (MF) is a myeloproliferative neoplasm that commonly harbors acquired somatic gene mutations in JAK2, CALR, or MPL. Despite treatment with the current standard of care, patients, significant unmet need exist for treatment naïve MF patients. 

- <50% of patients achieved SVR35
- The median duration of selinexor treatment as of the data cutoff in the 40mg cohort was 31.5 weeks (range 12-68 weeks).
- CVR35 at Week 12
- OS

Despite treatment with the current label, dose selections made for patients with high-risk disease 

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.

Selinexor is an oral XPO1 inhibitor that may inhibit multiple pathways relevant in MF including STAT, ERK, and AKT. Preclinical studies have shown potential synergy of selinexor and ruxolitinib in vitro and in vivo.